Last reviewed · How we verify

Epirubicin Injectable Product

The First Affiliated Hospital with Nanjing Medical University · Phase 3 active Small molecule

Epirubicin Injectable Product is a Anthracycline topoisomerase II inhibitor Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently in Phase 3 development for Breast cancer (adjuvant and metastatic), Gastric cancer, Ovarian cancer.

Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells.

Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells. Used for Breast cancer (adjuvant and metastatic), Gastric cancer, Ovarian cancer.

At a glance

Generic nameEpirubicin Injectable Product
SponsorThe First Affiliated Hospital with Nanjing Medical University
Drug classAnthracycline topoisomerase II inhibitor
TargetTopoisomerase II, DNA
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Epirubicin is an anthracycline chemotherapy agent that works by intercalating into the DNA double helix and inhibiting topoisomerase II, an enzyme essential for DNA replication and transcription. This prevents the separation of DNA strands and leads to accumulation of DNA breaks, triggering apoptosis in cancer cells. It is commonly used in combination chemotherapy regimens for solid tumors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Epirubicin Injectable Product

What is Epirubicin Injectable Product?

Epirubicin Injectable Product is a Anthracycline topoisomerase II inhibitor drug developed by The First Affiliated Hospital with Nanjing Medical University, indicated for Breast cancer (adjuvant and metastatic), Gastric cancer, Ovarian cancer.

How does Epirubicin Injectable Product work?

Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells.

What is Epirubicin Injectable Product used for?

Epirubicin Injectable Product is indicated for Breast cancer (adjuvant and metastatic), Gastric cancer, Ovarian cancer, Lymphomas.

Who makes Epirubicin Injectable Product?

Epirubicin Injectable Product is developed by The First Affiliated Hospital with Nanjing Medical University (see full The First Affiliated Hospital with Nanjing Medical University pipeline at /company/the-first-affiliated-hospital-with-nanjing-medical-university).

What drug class is Epirubicin Injectable Product in?

Epirubicin Injectable Product belongs to the Anthracycline topoisomerase II inhibitor class. See all Anthracycline topoisomerase II inhibitor drugs at /class/anthracycline-topoisomerase-ii-inhibitor.

What development phase is Epirubicin Injectable Product in?

Epirubicin Injectable Product is in Phase 3.

What are the side effects of Epirubicin Injectable Product?

Common side effects of Epirubicin Injectable Product include Cardiotoxicity / congestive heart failure, Myelosuppression (neutropenia, anemia, thrombocytopenia), Nausea and vomiting, Alopecia, Mucositis, Diarrhea.

What does Epirubicin Injectable Product target?

Epirubicin Injectable Product targets Topoisomerase II, DNA and is a Anthracycline topoisomerase II inhibitor.

Related